international vaccine institute ivi independent nonprofit international organization founded belief health children developing countries dramatically improved use new improved vaccines working collaboration international scientific community public health organizations governments industry ivi involved areas vaccine spectrum new vaccine design laboratory vaccine development evaluation field facilitating sustainable introduction vaccines countries needed created initially initiative un development programme undp ivi began formal operations independent international organization seoul republic korea currently ivi member states signatories parties world health organization signatories establishment agreement institute unique mandate work exclusively vaccine development introduction specifically people developing countries focus neglected diseases affecting dr seungil shin senior health advisor united nations development programme undp initiated study explore feasibility establishing international institute devoted vaccine research development within framework childrens vaccine initiative cvicitation needed based results shins feasibility study undp adopted formal proposal establish international vaccine institute ivi following call proposals host ivi asia pacific region undp republic korea reached agreement host center seoul undp opened interim ivi office campus seoul national university institute began initial work organizational developmentcitation needed undp south korean government jointly developed basic framework constitution ivi order establish ivi independent international organization undp korean government elected establish institute intergovernmental agreement un member states sanctioned vienna convention laws treaties needed october ivi establishment agreement opened signatures un headquarters new york city representatives bangladesh bhutan indonesia kazakhstan mongolia netherlands panama republic korea romania thailand vietnam uzbekistan first sign agreement followed shortly thereafter senegal philippinescitation needed countries followed brazil china egypt israel jamaica kyrgyzstan myanmar nepal pakistan papua new guinea peru sri lanka sweden tajikistan turkey signing may ivi establishment agreement entered force following submission instruments ratification south korea sweden uzbekistan ivi establishment agreement entered united nations depository treaties chapter ix health section september ivi headquarters agreement signed formal ceremony undp headquarters south koreas minister foreign affairs trade hon hong soonyoung ivi board chairman dr barry bloom headquarters agreement established ivi legal entity diplomatic immunity south korea becoming first international organization headquartered south korea accordance ivis independent status institute formally separated undp needed ivi headquarters building located seoul national universitys research park seoul south korea designed consortium consisting samwoo architects south korea payette associates boston us construction began completed building houses laboratories animal facilities offices auditorium library separate pilot plant facility intended production test lots vaccines training evaluation purposes constructed never completed due lack fundingcitation needed ivis first major initiative diseases impoverished domi program research technical assistance accelerate introduction new vaccines typhoid fever cholera shigellosis public health programs poor developing countries ivis domi program carried vaccination campaigns disease surveillance research studies bangladesh china india indonesia mozambique pakistan thailand vietnam conclusion domi program ivi synthesized diverse epidemiological clinical economic behavioral findings studies order facilitate informed decisionmaking policymakers national level use vaccines diseases targeted domi bill melinda gates foundation primary funder domi program million domi typhoid program initiated address barriers access typhoid vaccines developing world accelerate introduction modern typhoid vaccines countries needed domi typhoid utilized vipolysaccharide vips vaccine easily inexpensively produced manufacturers developing countries given single dose relatively thermostable domi typhoid operated five study sites heichi china kolkata india north jakarta indonesia karachi pakistan hue vietnam sites ivi experts conducted disease surveillance disease burden studies costofillness studies sociobehavioral studies vaccine demonstration projects ivi presented accumulated evidence domi typhoid case studies officials host country result policymakers pakistan indonesia vietnam agreed introduce schoolbased typhoid vaccination campaigns pilot basis results china uncovered previously unknown growing incidence rate paratyphoid infections chinas guangxi province led ivi launching paratyphoid china domi cholera program sought develop accelerate use affordable cholera vaccine choleraendemic countries domi cholera operated five study sites matlab bangladesh north jakarta indonesia kolkata india beira mozambique hue vietnam sites ivi conducted disease burden economic sociobehavioral studies cholera vaccination campaigns studies found high demand cholera vaccine high incidence rates children five years old younger ivis vaccination campaign beira saw children adults receive internationally licensed dukoral vaccine kolkata ivi vaccinated children adults using oral cholera vaccine produced vietnams vabiotech onset domi cholera internationally licensed cholera vaccine available dukoral twodose series vaccine expensive public use many poorest developing countries vabiotechs cholera vaccine originally developed vietnams national institute health epidemiology following technology transfer university gothenburg sweden licensed international use showed great promise lowcost vaccine developing world result gates foundation provided ivi additional funding establish cholera vaccine initiative cvi goal reformulating vabiotech vaccine international usecitation needed ivi established domi shigellosis program ultimate goal accelerating development introduction safe protective shigella vaccine control epidemic endemic disease domi shigella program ran disease surveillance sites six locations across southeast asia dhaka bangladesh hebei china karachi pakistan neighboring villages north jakarta indonesia nha trang vietnam saraburi province thailand program enhanced understanding effective shigella vaccine need established accurate disease burden countries operated program first evaluated oral shigella vaccine bangladesh failed elicit immune response high disease burden serotype diversity high levels amr discovered ivis surveillance sites underscored need vaccine protects common strains disease result ivis division laboratory sciences initiated multiyear program sequence shigella genome identify common proteins different shigella species could used develop vaccine common strains ivi initiated rotavirus diarrhea program provide policymakers developing countries disease burden evidence economic data needed ensure inclusion rotavirus vaccines national immunization programs running program conducted disease surveillance economic studies cambodia china india indonesia laos mongolia south korea sri lanka vietnam collaboration vietnams national institute hygiene epidemiology nihe ivi conducted phase ii trial gsks rotarix rotavirus vaccine khanh hoa vietnam collaboration nihe path merck ivi completed phase iii trial mercks rotateq rotavirus vaccine nha trang vietnam vaccinated pediatric dengue vaccine initiative product development partnership launched ivi accelerate introduction safe effective dengue vaccines children dengueendemic countries pdvi operated brazil cambodia colombia india indonesia laos malaysia mexico myanmar nicaragua sri lanka thailand vietnam pdvi made many contributions dengue vaccine development includingcitation needed pdvi transitioned dengue vaccine initiative successor pdvi dengue vaccine initiative iviled consortium world health organization sabin vaccine institute initiative vaccine research ivr international vaccine access center ivac johns hopkins university dvi continued work pdvi focused laying groundwork dengue vaccine decisionmaking vaccine introduction endemic areas consortium member responsible specific component information guidance documents regulatory training activities johns hopkins dengue vaccine financing strategic demand forecasting sabin communications advocacy besides leading consortium ivi generated evidence decisionmaking disease burden country vaccine introduction cases global investment case dvi operated brazil burkina faso cambodia colombia gabon india kenya thailand vietnam funding germanys federal ministry education research bmbf ivi continued support preclinical development dengue vaccines brazils butantan institute vietnams vabiotech licensure sanofi pasteurs dengvaxia vaccine dvi project came close ivi staff transitioned new project global dengue aedestransmitted disease consortium january ivi includes countries world health organization signatories establishment agreement signatories bangladesh bhutan brazil china ecuador egypt india indonesia israel jamaica kazakhstan kyrgyzstan lebanon liberia malta mongolia myanmar nepal netherlands oman pakistan panama papua new guinea peru philippines republic korea romania senegal sri lanka sweden world health organizationcitation needed ivi partnered corporations philanthropic organizations foundations governments media organizations around world major partners httpsenwikipediaorgwikiagreementontheestablishmentoftheinternationalvaccineinstitute